Mandate

Vinge advises Offentliga Hus i Norden AB (publ) in connection with its listing on Nasdaq First North Premier Growth Market

Vinge has advised Offentliga Hus i Norden AB (publ) (“Offentliga Hus”) in connection with its listing on Nasdaq First North Premier Growth Market (“Nasdaq First North Premier”). The prospectus was published on 13 October 2020 and the first day of trading on Nasdaq First North Premier was 23 October 2020.

The price in the offering was SEK 13.40 per share, corresponding to a market value of Offentliga Hus of SEK 3,430 million after the completion of the offering. The offering comprised 111,940,300 shares, of which 55,970,150 shares were newly issued shares and 55,970,150 were existing shares offered by Nordact AB.

Offentliga Hus is a growth-oriented property company with a focus on community service properties, where the tenants are predominantly, directly or indirectly, made up of public sector. The Company is geographically focused on larger and medium-sized cities in Sweden. By offering suitable premises at market conditions, Offentliga Hus are an attractive partner for the state, regions and municipalities in need of long-term and efficient property solutions.

Vinge’s team primarily consisted of David Andersson, William Kåge, Stephanie Stiernstedt and Lorin Arabi (Capital Markets and Public M&A), Maria Schultzberg, Henrik Wastenson and Victor Ericsson (Corporate tax), Mikael Ståhl and Felix Möller (Banking and Finance).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025